摘要
Introduction: Camrelizumab, a humanized immunoglobulin G4-kappa monoclonal antibody against programmed cell death protein 1, has exhibited antitumor activity and tolerability across various tumors, including lung cancers. We conducted this double-blind, randomized phase 3 trial to investigate the efficacy and safety of camrelizumab or placebo plus chemotherapy as first-line treatment for patients with advanced squamous NSCLC. The predictive value of circulating tumor DNA (ctDNA) dynamics was also analyzed. @@@ Methods: CameL-sq, a double-blind, randomized phase 3 trial (NCT03668496), was conducted in 53 centers in the People's Republic of China. A total of 389 patients with stage IIIB-IV squamous NSCLC were randomized (1:1) to receive 4 to 6 cycles of carboplatin plus paclitaxel with camrelizumab or placebo (every 3 wk), followed by maintenance therapy with camrelizumab or placebo. Peripheral blood ctDNA samples were collected at baseline and the time after two cycles of treatment. @@@ Results: Of 389 eligible patients, 193 patients allocated camrelizumab plus chemotherapy and 196 patients allocated placebo plus chemotherapy were included in the efficacy and safety analysis. The results revealed significantly prolonged progression-free survival (median, 8.5 vs. 4.9 mo; p <0.0001) and overall survival (median, not reached vs. 14.5 mo; p <0.0001) with camrelizumab chemotherapy versus placebo-chemotherapy. No unexpected treatment immune-related adverse events were observed in both groups. Biomarker analysis revealed that ctDNA clearance after two cycles of treatment was independently associated with dramatically longer progression-free survival (p <0.0001) and overall survival (p <0.0001) in camrelizumab plus chemotherapy group. @@@ Conclusions: Our findings support camrelizumab plus chemotherapy as a first-line treatment option in advanced squamous NSCLC. On-treatment ctDNA dynamics exhibited the potency to predict the efficacy of camrelizumab plus chemotherapy.
学科与关键词
- On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trialJiang, Tao; Chen, Jianhua; Xu, Xingxiang; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Zhang, Yaxi; Zhang, Jiao; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun*; Ren, Shengxiang*Molecular Cancer, 2022, 21(1): 4.被引 25
- CamreliZumab Plus Carboplatin and PemetreXed as First-Line Treatment for Advanced NonsQuamous NSCLC: EXtended Follow-Up of CameL Phase 3 TrialZhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, YongQian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, GuangyuJournal of Thoracic Oncology, 2023, 18(5): 628-639.被引 3
- First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trialZhou, C.; Cheng, Y.; Chen, J.; Xu, X.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Shi, J.; Cao, P.; Wang, D.; Lv, D.; Luo, H.; Yang, Z.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 2
